Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338191 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL4291 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL3119262 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8192290 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5835621 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5544656 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL8532996 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL6374631 | 1.00 | GRM5 (0.49) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL27504027 | 0.98 | GRM5 (0.48) | GRM5CA2SLC6A2ADRA1AHTR2B | |
| SCHEMBL5196221 | 0.91 | GRM5 (0.57) | GRM5CA2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| EP-0925292-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING SUBSTITUTED CHROMANOL DERIVATIVES | PFIZER (US) | 2003-09-10 | — | — | EP | claimed |
| US-12465580-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-11-11 | — | — | US | disclosed |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2025-10-14 | — | — | US | disclosed |
| CN-120136861-A | 2-Aryl-6-aryloxy methylmorpholine derivative and application thereof | 安徽景星医药技术有限公司 | 2025-06-13 | — | — | CN | disclosed |
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| EP-3720431-B1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-10-30 | — | — | EP | disclosed |
| EP-3288550-B1 | STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR THEIR USE IN TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-06-05 | — | — | EP | disclosed |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-20240156760-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | BASF AS (NO) | 2024-05-16 | — | — | US | disclosed |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | BASF AS (NO) | 2024-03-12 | — | — | US | disclosed |
| US-5380925-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| WO-1994011361-A1 | PYRAN-2-ONES AND 5,6-DIHYDROPYRAN-2-ONES USEFUL FOR TREATING HIV AND OTHER RETROVIRUSES | THE UPJOHN COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| WO-1994007849-A1 | PROCESS FOR THE STEREOSELECTIVE SYNTHESIS OF 3-SUBSTITUTED 2-THIOMETHYL PROPIONIC ACIDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-04-14 | — | — | WO | disclosed |
| US-5264577-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993021176-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| WO-1993015042-A1 | PROCESS FOR THE PREPARATION OF D(-) AND L(+)-3,3-DIPHENYLALANINE AND D(-) AND L(+)-SUBSTITUTED 3,3-DIPHENYLALANINES AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-08-05 | — | — | WO | disclosed |
| US-5198548-A | Chemical intermediates for angiotensins | WARNER-LAMBERT COMPANY (US) | 1993-03-30 | — | — | US | disclosed |
| US-5179208-A | Analgesics | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1993-01-12 | — | — | US | disclosed |
| US-5145993-A | Process for preparing D-2-(6-methoxy-2-naphthyl)-propionic acid and intermediate thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 1992-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12465580-B2 | Substituted fatty acids for treating non-alcoholic steatohepatitis | SLC10A1, LIPC, FABP1 | GRM5 1587/4885CA2 2416/4885SLC6A2 778/4885 |
| US-20240156769-A1 | FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | CPT1A, NR1H2, NR1H3 | GRM5 1595/4885CA2 3197/4885SLC6A2 2556/4885 |
| US-20240156760-A1 | SUBSTITUTED FATTY ACIDS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | SLC10A1, LIPC, FABP1 | GRM5 1587/4885CA2 2416/4885SLC6A2 778/4885 |
| US-12440466-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H2, NR1H3 | GRM5 1595/4885CA2 3197/4885SLC6A2 2556/4885 |
| US-11925614-B2 | Fatty acid derivatives for treating non-alcoholic steatohepatitis | CPT1A, NR1H3, NR1H2 | GRM5 1534/4885CA2 3049/4885SLC6A2 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.